Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14640087 | 0.84 | KIF11 (0.42) | KIF11PTGS1PTGS2SMN1; SMN2NFE2L2 | |
| SCHEMBL11962356 | 0.82 | KIF11 (0.41) | KIF11PTGS1PTGS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL16348230 | 0.82 | KIF11 (0.45) | KIF11PTGS1PTGS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL1690352 | 0.81 | ALDH1A1 (0.44) | KIF11PTGS1PTGS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL764426 | 0.81 | CYP11B2 (0.53) | KIF11CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL31410005 | 0.80 | KIF11 (0.44) | KIF11PTGS1PTGS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL31490900 | 0.79 | KIF11 (0.42) | KIF11SMN1; SMN2TSHRNFE2L2CYP11B1 | |
| SCHEMBL20089653 | 0.79 | KIF11 (0.43) | KIF11PTGS1PTGS2SMN1; SMN2NFE2L2 | |
| SCHEMBL10193081 | 0.79 | KIF11 (0.43) | KIF11PTGS1PTGS2SMN1; SMN2NFE2L2 | |
| SCHEMBL441530 | 0.78 | ALDH1A1 (0.42) | PTGS1PTGS2ALDH1A1SMN1; SMN2NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230329095-A1 | Novel Compound, Coating Composition Comprising Same, Organic Light-Emitting Device Using Same, and Manufacturing Method Therefor | LG CHEM, LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230329095-A1 | Novel Compound, Coating Composition Comprising Same, Organic Light-Emitting Device Using Same, and Manufacturing Method Therefor | LG CHEM, LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100120762-A1 | Triazine derivatives as inhibitors of phosphodiesterases | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7453002-B2 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-7453002-B2 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-7429604-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-09-30 | — | — | US | disclosed |
| US-7402674-B2 | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH, (DE) | 2008-07-22 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | KIF11 337/4885PTGS1 4039/4885PTGS2 4263/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KIF11 4469/4885PTGS1 2769/4885PTGS2 3794/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KIF11 4469/4885PTGS1 2769/4885PTGS2 3794/4885 |
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | KIF11 3176/4885PTGS1 1662/4885PTGS2 2088/4885 |
| US-20230329095-A1 | Novel Compound, Coating Composition Comprising Same, Organic Light-Emitting Device Using Same, and Manufacturing Method Therefor | NOTUM, OR51E2, ORMDL3 | KIF11 954/4885PTGS1 1395/4885PTGS2 3385/4885 |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | PDE2A, PDE5A, PDE3A | KIF11 3875/4885PTGS1 320/4885PTGS2 325/4885 |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | KIF11 4868/4885PTGS1 864/4885PTGS2 337/4885 |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | MKI67, CCNI, CDKN1A | KIF11 2888/4885PTGS1 380/4885PTGS2 508/4885 |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | KIF11 4868/4885PTGS1 864/4885PTGS2 337/4885 |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | KIF11 1995/4885PTGS1 2576/4885PTGS2 2651/4885 |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | KIF11 2545/4885PTGS1 1184/4885PTGS2 2800/4885 |
| US-20100120762-A1 | Triazine derivatives as inhibitors of phosphodiesterases | PDE2A, PDE5A, PDE12 | KIF11 3404/4885PTGS1 403/4885PTGS2 99/4885 |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | APLNR, AGTR1, AGTR2 | KIF11 4542/4885PTGS1 773/4885PTGS2 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.